Alvin Zipursky Editor-in-Chief
The optimal management of hyperbilirubinemia in healthy term infants remains unknown (1, 2) . "Few issues in neonatal medicine have generated such long-standing controversy as the possible adverse consequences of neonatal jaundice and when to begin treatment. Questions regarding potentially detrimental neurologic effects from elevated serum bilirubin levels prompt continuing concern and debate, particularly with regard to the management of the otherwise healthy term neonate without risk factors for hemolysis" (2) . The common goal expressed in the guidelines by the Committee on Fetus and Newborn, American Academy of Pediatrics (2) and the Fetus and Newborn Committee of the Canadian Paediatric Society (1) is to avoid plasma bilirubin concentrations that may results in kernicterus.
The apparent increase in the incidence of kernicterus among "healthy term infants" in North America (3) and Europe (4) may be due to a number of factors including better ascertaining and reporting of cases, or that the current guidelines are not followed or are not appropriate.
The case control study by Soorani-Lunsing et al. (5) and the commentaries published in the current issue of the journal should be seen as an incentive for continued research into hyperbilirubinemia of the healthy term infant. The authors found that moderate hyperbilirubinemia was associated with a significant increase in minor neurological dysfunction throughout the first year of life. They conclude that total serum bilirubin levels of 335 mol/L should be avoided.
In the current report 20 cases with a plasma bilirubin level Ͼ220 mol/L were collected over an 8 months study period. The authors do not mention if these were consecutive casesone would have expected many more cases in an 8 months study period. These cases were likely selected from a larger group of patients, who would have met study inclusion criteria. One would also have expected more eligible controls during the study period. We do therefore not know how either the cases or the controls were selected from the larger group of potentially eligible patients. In case control studies usually at least 2-3 controls are selected for each case. The authors used a 1:1 ratio. There was no preset sample size calculation. Because of the small sample-size the 95% confidence interval around the point estimate of the outcome of developing minor neurological dysfunction at 12 months is very wide [OR 9.47 (95% CI ϭ 1-67; 53.65)]. Plasma bilirubin levels were not measured in the control group. Thus plasma bilirubin or hyperbilirubinemia could not be entered as a variable in the logistic regression model. Only group status of having visible jaundices or not could be entered. As clinicians we are not very astute at estimating the total plasma bilirubin level by visual inspection of the baby. It is exceptional in a case control study that the key variable under study, in this case total plasma bilirubin, was not measured in both cases and control. A dose response could therefore only be studied among the cases.
The cesarean section rates differed among cases and controls; maternal education also differed between the two groups (possibly because of the small sample size this did not reach statistical significance). The authors provide only few base-line characteristics of the cases and controls.
Four babies in the study group and 2 in the control group were born preterm (36 wk). The practice parameters by the American Academy of Pediatrics and the Canadian Paediatric Society address hyperbilirubinemia only in term infants (37 wk or more) (1, 2). Preterm infants should have been excluded from the current study if the objective of the study was to overturn the current recommendations.
I am not certain that the assessment tools used at follow-up have been validated. The early assessments were not performed blinded to group allocation. In the newborn period there was a wide age range among the infants at the time of assessment.
The question asked by the authors: "Are moderate degrees of hyperbilirubinemia in healthy term neonates really safe for the brain?" is an important one, which needs an urgent answer. In my opinion and because of the serious methodological flaws in the current study the authors have not provided an unbiased answer to their question. This can only be achieved by conducting a well-designed cohort study. Such a study should have an appropriate sample size, measure plasma bilirubin levels in all enrolled infants and use validated assessment tools for the long-term (at least 18 months of age) outcomes. Individuals blinded to the neonatal conditions should undertake the assessments of neuro-motor function at 18 months.
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